Aclaris Therapeutics ACRS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's total liabilities?
- Aclaris Therapeutics (ACRS) reported total liabilities of $55.07M in Q1 2026.
- How has Aclaris Therapeutics's total liabilities changed year-over-year?
- Aclaris Therapeutics's total liabilities increased by 1.9% year-over-year, from $54.03M to $55.07M.
- What is the long-term trend for Aclaris Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's total liabilities has grown at a 11.6% compound annual growth rate (CAGR), from $33.13M to $57.38M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.